IL130184A0 - EHV-1 vectors - Google Patents

EHV-1 vectors

Info

Publication number
IL130184A0
IL130184A0 IL13018497A IL13018497A IL130184A0 IL 130184 A0 IL130184 A0 IL 130184A0 IL 13018497 A IL13018497 A IL 13018497A IL 13018497 A IL13018497 A IL 13018497A IL 130184 A0 IL130184 A0 IL 130184A0
Authority
IL
Israel
Prior art keywords
virus
ehv
vectors
replicate
manipulation
Prior art date
Application number
IL13018497A
Other languages
English (en)
Original Assignee
Univ Leeds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leeds filed Critical Univ Leeds
Publication of IL130184A0 publication Critical patent/IL130184A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16721Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Feedback Control In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
IL13018497A 1996-12-14 1997-12-12 EHV-1 vectors IL130184A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9626029.4A GB9626029D0 (en) 1996-12-14 1996-12-14 EVH-1 vectors
PCT/GB1997/003438 WO1998027216A1 (en) 1996-12-14 1997-12-12 Ehv-1 vectors

Publications (1)

Publication Number Publication Date
IL130184A0 true IL130184A0 (en) 2000-06-01

Family

ID=10804475

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13018497A IL130184A0 (en) 1996-12-14 1997-12-12 EHV-1 vectors

Country Status (11)

Country Link
US (2) US6387685B1 (de)
EP (1) EP0953054B1 (de)
JP (1) JP2001506854A (de)
AT (1) ATE272713T1 (de)
AU (1) AU735339B2 (de)
CA (1) CA2275546A1 (de)
DE (1) DE69730153D1 (de)
GB (2) GB9626029D0 (de)
IL (1) IL130184A0 (de)
NZ (1) NZ336047A (de)
WO (1) WO1998027216A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704046D0 (en) * 1997-02-27 1997-04-16 Univ Leeds Arrestable therapeutic
EP1129722A1 (de) * 2000-02-17 2001-09-05 Boehringer Ingelheim Vetmedica Gmbh GM-negative EHV Mutanten
AR040601A1 (es) * 2002-07-19 2005-04-13 Boehringer Ingelheim Vetmed Mutantes ehv negativos de gm sin elementos heterologos
EP1394258A1 (de) * 2002-08-30 2004-03-03 Geneart GmbH Nicht-menschliche Herpesviren als Vektoren
HUE026386T2 (en) 2009-03-02 2016-06-28 Univ California Tumor-selective adenovirus e1a and e1b mutants
MX2019003161A (es) * 2016-09-20 2019-05-27 Boehringer Ingelheim Vetmedica Gmbh Nuevo sitio de insercion orf70 de ehv.
CA3036310A1 (en) * 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New swine influenza vaccine
BR112019005964A2 (pt) 2016-09-27 2019-06-18 Epicentrx, Inc. proteínas de fusão imunomoduladoras
EA201990822A1 (ru) 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
JP2020536518A (ja) 2017-09-27 2020-12-17 エピセントアールエックス,インコーポレイテッド 免疫調節融合タンパク質
US11384365B2 (en) * 2018-03-19 2022-07-12 Boehringer Ingelheim Vetmedica Gmbh EHV with inactivated UL18 and/or UL8
EP3773649A4 (de) 2018-03-28 2022-02-23 EpicentRx, Inc. Personalisierte krebsvakzine
EP3921334A1 (de) * 2019-02-08 2021-12-15 Krystal Biotech, Inc. Zusammensetzungen und verfahren zur verabreichung von cftr-polypeptiden
CA3160199A1 (en) * 2019-12-20 2021-06-24 Suma Krishnan Compositions and methods for gene delivery to the airways and/or lungs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292653A (en) * 1989-09-27 1994-03-08 Novagene, Inc. Equine herpesvirus 1 tk mutants
GB9014951D0 (en) 1990-07-06 1990-08-29 Univ Glasgow Equine herpesvirus-4 tk vaccine
DE4110962A1 (de) * 1991-04-05 1992-10-08 Bayer Ag Equine herpesviren (ehv), die fremd-dna enthalten, verfahren zu ihrer herstellung und ihre verwendung in impfstoffen
GB9213882D0 (en) * 1992-06-30 1992-08-12 Univ Court Of The University O Live modified equine herpesvirus-4 vaccine
DK0654089T3 (da) * 1992-08-07 2003-10-13 Syntro Corp Rekombinante ekvine herpesvira
US5741696A (en) * 1992-08-07 1998-04-21 Syntro Corporation Recombinant equine herpesviruses
EP0871755A1 (de) * 1995-03-23 1998-10-21 Cantab Pharmaceuticals Research Limited Vektoren zur verabreichung von genen

Also Published As

Publication number Publication date
JP2001506854A (ja) 2001-05-29
CA2275546A1 (en) 1998-06-25
EP0953054B1 (de) 2004-08-04
US20020090716A1 (en) 2002-07-11
NZ336047A (en) 2001-02-23
GB9912127D0 (en) 1999-07-28
DE69730153D1 (de) 2004-09-09
US6387685B1 (en) 2002-05-14
GB2335426B (en) 2001-06-13
ATE272713T1 (de) 2004-08-15
GB9626029D0 (en) 1997-01-29
AU735339B2 (en) 2001-07-05
GB2335426A (en) 1999-09-22
EP0953054A1 (de) 1999-11-03
US6706515B2 (en) 2004-03-16
WO1998027216A1 (en) 1998-06-25
AU7738798A (en) 1998-07-15

Similar Documents

Publication Publication Date Title
FR2727689B1 (de)
GB2335426B (en) EHV-1 Vectors
CZ63995A3 (en) Virus vectors and their use in gene therapy
IL122120A (en) Recombinant mva virus containing a foreign gene inserted in a naturally occuring deletion within the genome
AU9254801A (en) Methods for treating cell proliferative disorders and viral infections
CA2206179A1 (en) Vectors for tissue-specific replication
BG100974A (en) Vaccines against papillomavirus
ZA943358B (en) Viral vectors and their use in gene therapy
ZA942778B (en) Recombinant viruses, and their preparation and use in gene therapy.
PL339735A1 (en) Pappiloma virus capsomer vaccine compositions and methods of applying them
ZA949104B (en) Recombinant viruses and their use in gene therapy
WO2002092826A3 (en) Composition and method for treating cancer using herpes virus
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
ZA952563B (en) Recombinant viruses their preparation and their use in gene therapy
IL150984A0 (en) Modified cytokines for use in cancer therapy
GB9618477D0 (en) Gene therapy
IL111682A0 (en) Recombinant viruses and their use in gene therapy
AU4166997A (en) Use of herpes simplex virus orf p protein in repression of viral protein synthesis and related methods
IL109761A0 (en) Oligopeptides derived from c-reactive protein fragments
ZA952242B (en) Recombinant viruses their preparation and their use in gene therapy
HRP970693B1 (en) Cycloalkyl inhibitors of protein farnesyltransferase
IL112992A0 (en) Recombinant viruses, their preparation and their use in gene therapy
WO1999024052A3 (en) Use of protein h as cytostatic agent
GR960100092A (el) Νεα (2η) φαρμακευτικη χρηση του σκορδου για την παρασκευη οποιασδηποτε μορφης φαρμακου για την θεραπειαν του επιχειλιου ερπητος και του ερπητος των γεννητικων οργανων.
IL112994A0 (en) Recombinant viruses, their preparation and their use in gene therapy